Bloodstream infections in patients with solid tumors: Associated factors, microbial spectrum and outcome

Infection

Volumn 32, Issue 2, 2004, Pages 65-71

  Anatoliotaki, M ^b   Valatas, V ^b   Mantadakis, E ^b   Apostolakou, H ^b   Mavroudis, D ^b   Georgoulias, V ^b   Rolston, K V ^a   Kontoyiannis, D P ^a   Galanakis, E ^b   Samonis, G ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTOTOXIC AGENT; IMMUNOMODULATING AGENT;

ADULT; AGED; ANAEROBIC BACTERIUM; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CLINICAL MEDICINE; COMMUNICABLE DISEASE; DISEASE ASSOCIATION; FEMALE; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GREECE; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; NEUTROPENIA; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SHOCK; SOLID TUMOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BACTEREMIA; BLOOD-BORNE PATHOGENS; COHORT STUDIES; COMORBIDITY; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GREECE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 11144356132     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-004-3049-5     Document Type: Article

References (36)

1. Singer C, Kaplan MH, Armstrong D: Bacteremia and fungemia complicating neoplastic disease. A study of 364 episodes. Am J Med 1977; 62: 731-742.
2. Whimbey E, Kiehn TE, Brannon P, Blevins A, Armstrong D: Bacteremia and fungemia in patients with neoplastic disease. Am J Med 1987; 82: 723-730.
3. Viscoli C, Castagnola E: Planned progressive antimicrobial therapy in neutropenic patients. Br J Haematol 1998; 102: 879-888.
4. Koll BS, Brown AE: The changing epidemiology of infections at cancer hospitals. Clin Infect Dis 1993; 17 (Suppl 2): S322-328.
5. Schimpff SC: Infections in the cancer patient-diagnosis, prevention and treatment. In: Mandell GL, Bennett JE, Dolin R (eds): Principles and practice of infectious diseases. Churchill Livingstone, New York 1995, pp 2666-2675.
6. De Pauw BE, Donnelly PJ: Infection in the immunocompromised host: General principles. In: Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of infectious diseases. Churchill Livingstone, Philadelphia 2000, pp 3079-3089.
7. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F: Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996; 15: 291-296.
8. Schimpff SC, Gaya H, Klastersky J, Tattersall MH, Zinner SH: The EORTC international antimicrobial therapy project group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978; 137: 14-29.
9. The EORTC International Antimicrobial Therapy Cooperative Group: Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692-1698.
10. EORTC International Antimicrobial Therapy Cooperative Group: Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer 1990; 26: 569-574.
11. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M,Viscoli C, Glauser MP: The International Antimicrobial Therapy Cooperative Group of the EORTC. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39: 445-452.
12. Escande MC, Herbrecht R: Prospective study of bacteraemia in cancer patients. Results of a French multicentre study. Support Care Cancer 1998; 6: 273-280.
13. Elting LS, Bodey GP, Fainstein V: Polymicrobial septicemia in the cancer patient. Medicine (Baltimore) 1986; 65: 218-225.
14. Members of the American College of Chest Physicians/ Society of Critical Care Medicine consensus conference committee: American College of Chest Physicians/Society of Critical Care Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
15. Thorpe TC, Wilson ML, Turner JE, DiGuiseppi JL, Willert M, Mirrett S, Relier LB: BacT/Alert: an automated colorimetric microbial detection system. J Clin Microbiol 1990; 28: 1608-1612.
16. Isenberg HD, Baron EJ, D'Amato RF, Johnson RC, Murray PR, Rodgers FG, von Graevenitz A: Recommendations for the isolation of bacteria from clinical specimens. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ (eds): Manual of clinical microbiology. American Society for Microbiology, Washington DC 1991, pp 216-221.
17. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M100-S11. National Committee for Clinical Laboratory Standards, Villanova, Pa, 2001.
18. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ: Healthcare- associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137: 791-797.
19. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections 1988. Am J Infect Contr 1988; 16: 128-140.
20. Velasco E, Thuler LC, Martins CA, Nucci M, Dias LM, Goncalves VM: Epidemiology of bloodstream infections at a cancer center. Sao Paulo Med J 2000; 118: 131-138.
21. McCabe WR, Jackson GG: Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med 1962; 110: 83-91.
22. Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
23. Coullioud D, van der Auwera P, Viot M, Lasset C. CEMIC (French-Belgian Study Club of Infectious Diseases in Cancer): Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. Support Care Cancer 1993; 1: 34-46.
24. Del Favero A, Menichetti F, Bucaneve G, Minotti V, Pauluzzi S: Septicaemia due to Gram-positive cocci in cancer patients. J Antimicrob Chemother 1988; 21 (Suppl C):157-165.
25. Viscoli C:The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 1998; 41 (Suppl D): 65-80.
26. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken I, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP: The International Antimicrobial Therapy Cooperative Group of the EORTC and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108-1115.
27. von Eiff C, Heilmann C, Peters G: New aspects in the molecular basis of polymer-associated infections due to staphylococci. Eur J Clin Microbiol Infect Dis 1999; 18: 843-846.
28. Tenney JH, Moody MR, Newman KA, Schimpff SC, Wade JC, Costerton JW, Reed WP: Adherent microorganisms on luminal surfaces of long-term intravenous catheters. Importance of Staphylococcus epidermidis in patients with cancer. Arch Intern Med 1986; 146: 1949-1954.
29. Schimpff SC, Scott DA, Wade JC: Infections in cancer patients: some controversial issues. Support Care Cancer 1994; 2: 94-104.
30. EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group: Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-958.
31. Handwerger S, Raucher B, Altarac D, Monka J, Marchione S, Singh KV, Murray BE, Wolff J, Walters B: Nosocomial outbreak due to Enterococcusfaecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993; 16: 750-755.
32. Handwerger S, Perlman DC, Altarac D, McAuliffe V: Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis 1992; 14: 655-661.
33. Boyce JM: Methicillin-resistant Staphylococcus aureus: a continuing infection control challenge. Eur J Clin Microbiol Infect Dis 1994; 13: 45-49.
34. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP:Vancomycin-resistant Enterococcusfaecium BSI: risk factors for infection. Clin Infect Dis 1995; 20: 1126-1133.
35. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP: Nosocomial bloodstream Infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-244.
36. Spanik S, Sufliarsky J, Mardiak J, Sorkovska D, Trupl J, Kunova A, Kukuckova E, Rusnakova V, Demitrovicova A, Pichna P, Krupova I, Kralovicova K, Mateicka F, West D, Krcmery V Jr: Predictors of mortality in bacteremic cancer patients: retrospective analysis of 64 deaths occurring among 262 bacteremic episodes. Support Care Cancer 1998; 6: 291-294.